Orla Gray

Since the last edition of this book, 'no evidence of disease activity' (NEDA) has been proposed as a new treatment target, early data on the first pharmacological treatments for progressive MS have emerged, and the first remyelination trial has shown positive effects on nerve repair. It is with this sense of optimism that the authors of 'Fast Facts: Multiple Sclerosis' have detailed the latest developments for use in clinical practice by all members...